ATE283282T1 - Epitope des shigella-artigen toxins und ihre verwendung als impfstoff und in der diagnose - Google Patents

Epitope des shigella-artigen toxins und ihre verwendung als impfstoff und in der diagnose

Info

Publication number
ATE283282T1
ATE283282T1 AT98935164T AT98935164T ATE283282T1 AT E283282 T1 ATE283282 T1 AT E283282T1 AT 98935164 T AT98935164 T AT 98935164T AT 98935164 T AT98935164 T AT 98935164T AT E283282 T1 ATE283282 T1 AT E283282T1
Authority
AT
Austria
Prior art keywords
shigella
toxin
epitopes
diagnostics
vaccine
Prior art date
Application number
AT98935164T
Other languages
English (en)
Inventor
James Peter Burnie
Ruth Christine Matthews
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Application granted granted Critical
Publication of ATE283282T1 publication Critical patent/ATE283282T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98935164T 1997-07-21 1998-07-17 Epitope des shigella-artigen toxins und ihre verwendung als impfstoff und in der diagnose ATE283282T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715177A GB9715177D0 (en) 1997-07-21 1997-07-21 Medicament
PCT/GB1998/002156 WO1999005169A1 (en) 1997-07-21 1998-07-17 Epitopes of shigella like toxin and their use as vaccine and in diagnosis

Publications (1)

Publication Number Publication Date
ATE283282T1 true ATE283282T1 (de) 2004-12-15

Family

ID=10816080

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98935164T ATE283282T1 (de) 1997-07-21 1998-07-17 Epitope des shigella-artigen toxins und ihre verwendung als impfstoff und in der diagnose

Country Status (11)

Country Link
US (1) US6410024B1 (de)
EP (1) EP0998493B1 (de)
JP (1) JP4397523B2 (de)
AT (1) ATE283282T1 (de)
AU (1) AU747197B2 (de)
CA (1) CA2295940C (de)
DE (1) DE69827800T2 (de)
ES (1) ES2234132T3 (de)
GB (1) GB9715177D0 (de)
PT (1) PT998493E (de)
WO (1) WO1999005169A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
JP3804791B2 (ja) 2000-06-07 2006-08-02 セイコーエプソン株式会社 インクジェット記録用インク、記録方法、記録物およびインクジェット記録装置
US20100298238A1 (en) * 2007-10-08 2010-11-25 Rutgers, The State University Nontoxic shiga-like toxin mutant compositions and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955293A (en) * 1989-10-17 1999-09-21 New England Medical Center Hospitals, Inc. Assays for shiga toxin and shiga-like toxins
US5552144A (en) * 1992-01-22 1996-09-03 Microcarb, Inc. Immunogenic shiga-like toxin II variant mutants
AU667533B2 (en) * 1992-03-26 1996-03-28 Microcarb, Inc. Monospecific polyclonal antibodies to shiga-like toxins
US5719064A (en) * 1992-08-31 1998-02-17 Oklahoma Medical Research Foundation Peptide diagnostics and therapeutics for spondyloarthropathies
US5897475A (en) * 1994-10-05 1999-04-27 Antex Biologics, Inc. Vaccines comprising enhanced antigenic helicobacter spp.
CA2218601A1 (en) * 1995-03-24 1996-10-03 Ophidian Pharmaceuticals, Inc. Treatment for verotoxin-producing escherichia coli
JP2001500730A (ja) 1996-09-10 2001-01-23 ヘンリー エム ジャクソン ファンデーション フォージ アドバンスメント オブ ミリタリー メディシン ヒスチジン―タグ付き志賀毒素およびトキソイド、該毒素およびトキソイドとの融合タンパク質ならびにそれらの精製及び調製方法

Also Published As

Publication number Publication date
PT998493E (pt) 2005-03-31
JP4397523B2 (ja) 2010-01-13
WO1999005169A1 (en) 1999-02-04
DE69827800D1 (de) 2004-12-30
DE69827800T2 (de) 2005-11-24
EP0998493B1 (de) 2004-11-24
CA2295940C (en) 2010-06-15
US6410024B1 (en) 2002-06-25
JP2001510850A (ja) 2001-08-07
AU747197B2 (en) 2002-05-09
CA2295940A1 (en) 1999-02-04
ES2234132T3 (es) 2005-06-16
GB9715177D0 (en) 1997-09-24
EP0998493A1 (de) 2000-05-10
AU8452098A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
ATE302411T1 (de) Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens
BE2012C001I2 (de)
TR200202799T3 (tr) AB peptidini sekanslayan insanlaştırılmış antikorlar
ATE460946T1 (de) Gebrauch von bispezifischen antikörpern in diagnose und therapie
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
DE59914538D1 (de) Tetravalente Antikörperkonstrukte
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
MX9701859A (es) Anticuerpos monoclonales en contra de antigenos asociados con carcinoma de colon humano, y usos de los mismos.
ATE232902T1 (de) Anti-egfr einkettige fvs und anti-egfr antikoerper
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
ZA945364B (en) Antibodies specific for human prostate glandular kallikrein
ATE524196T1 (de) An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
DE602004028262D1 (de) B. pertussis antigene und ihre verwendung bei der vakzinierung
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
WO2003024191A3 (en) Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
DE69928384D1 (de) Behandlung und nachweis von staphylokokkeninfektionen
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
ATE283282T1 (de) Epitope des shigella-artigen toxins und ihre verwendung als impfstoff und in der diagnose
ATE208403T1 (de) Antiidiotypische antikörper die eine immunantwort gegen den rezeptor für epidermalen wachstumsfaktor induzieren
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
DK0783520T3 (da) Bredt reaktive opsoniske antistoffer, som er reaktive mod fælles stafylokok-antigener
AU4098201A (en) Method for diagnosing efficacy of xenotypic antibody therapy

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0998493

Country of ref document: EP

REN Ceased due to non-payment of the annual fee